Milestone Pharma Boosts Access to CARDAMYST Nasal Spray with Express Scripts Coverage, Expanding PSVT Treatment Access

Milestone Pharmaceuticals Inc. announced that Express Scripts has added CARDAMYST™ (etripamil) nasal spray to its commercial national formularies, effective March 27, 2026. This inclusion significantly expands access to the treatment, making it more affordable and widely available to commercially insured patients across the United States.

CARDAMYST™ is the first FDA-approved, self-administered nasal spray designed to treat acute episodes of paroxysmal supraventricular tachycardia (PSVT) by restoring normal heart rhythm in adults. The condition affects an estimated two million people in the U.S. and is characterized by sudden, rapid heartbeats that can cause symptoms such as palpitations, shortness of breath, chest discomfort, and dizziness.

“We have been working diligently to expand access to CARDAMYST for patients with PSVT since before the drug’s FDA approval in December 2025. This decision by Express Scripts represents the first contracted formulary acceptance of CARDAMYST by a major payor and thereby significantly improves access to this important new treatment option,” said Lorenz Muller, Chief Commercial Officer, Milestone Pharmaceuticals. “We are committed to making CARDAMYST affordable and accessible to the patient community, and we expect coverage to ramp up as we continue to engage with other insurance providers.”

PSVT episodes can be unpredictable and distressing, often disrupting daily life and leading patients to seek emergency care or invasive procedures like cardiac ablation. The lack of convenient and effective treatment options has been a challenge for both patients and healthcare providers.

By adding CARDAMYST™ to its formularies, Express Scripts is helping address this unmet need by improving access to a non-invasive, fast-acting treatment option that patients can use outside of hospital settings, potentially reducing the burden on emergency care services.